Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus zanubrutinib for elderly patients with central nervous system lymphoma
ChiCTR2100042513Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab and zanubrutinib in central nervous system lymphoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Overall response rate and Safety. Started Feb 2021; status: recruiting.
02
Drugs
rituximabzanubrutinib
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on ChiCTR2100042513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042513.